At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 58 enrolled
Drug / intervention
rDEN3/4delta30(ME) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 13, 2006·Updated Dec 14, 2010
In Brief
A Phase 1 clinical trial evaluating rDEN3/4delta30(ME) and Placebo for Dengue. Completed, enrolled 58 participants across 1 site.
Detailed Summary
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesUnited States
CollaboratorsJohns Hopkins Bloomberg School of Public Health
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartOct 2006
Primary CompletionSep 2008
TodayJul 2026
First PostedSep 13, 2006
Enrollment StartOct 1, 2006
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.8 years ago
Interventions
rDEN3/4delta30(ME)biological
Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
Placebobiological
Placebo for rDEN3/4delta30(ME)